SEARCH:   Advanced

Blood, 13 August 2009, Vol. 114, No. 7, pp. 1299-1305. Prepublished online as a Blood First Edition Paper on June 11, 2009; DOI 10.1182/blood-2009-03-211953. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2009-03-211953v1 blood-2009-03-211953v2 114/7/1299    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Hoering, A. Articles by Barlogie, B. PubMed PubMed Citation Articles by Hoering, A. Articles by Barlogie, B. Related Collections Free Research Articles Lymphoid Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols Antje Hoering1, John Crowley1, John D Shaughnessy, Jr2, Klaus Hollmig2, Yazan Alsayed2, Jackie Szymonifka1, Sarah Waheed2, Bijay Nair2, Frits van Rhee2, Elias Anaissie2, and Bart Barlogie2 1 Cancer Research and Biostatistics, Seattle, WA; and 2 Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock Landmark analyses are used to investigate the importance for survival of achieving complete response (CR), an important initial goal of myeloma therapy. With median times to CR in Total Therapy (TT) trials of approximately 1 year, this approach excludes a sizeable fraction of patients dying before such a landmark. To permit inclusion of all trial participants, we investigated the prognostic implications of both onset and duration of CR as time-dependent variables. Superseding the adverse effects of cytogenetic abnormalities and other standard prognostic parameters, both failure to achieve CR (non-CR) and, especially, loss of CR (los-CR) were independently associated with inferior survival in TT1, TT2, and TT3 protocols. In the context of gene array–defined risk, available in TT2 and TT3 subsets, both los-CR and non-CR terms were retained in the survival model as dominant adverse variables, stressing the prognostic importance of sustaining CR status, especially in high-risk disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. B. Bartel, J. Haessler, T. L. Y. Brown, J. D. Shaughnessy Jr, F. van Rhee, E. Anaissie, T. Alpe, E. Angtuaco, R. Walker, J. Epstein, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma Blood, September 3, 2009; 114(10): 2068 - 2076. [Abstract] [Full Text] [PDF] S. Lonial Risky business in myeloma Blood, July 16, 2009; 114(3): 496 - 497. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020